News

Transcript of Sustainability Meeting

Presentation Materilals of Sustainability Meeting

Acceptance of a New Drug Application for the Gram-Negative Bacterial Infection Treatment, Cefiderocol, in Australia

2024 SHIONOGI Integrated Report have been issued

Transcript of the FY2024 2Q Financial Results Conference

Actions to Achieve Management that is Conscious of Capital Costs and Stock Prices

Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19

Notice Regarding Interim Dividend for the Fiscal Year Ending March 31, 2024

Notice of Revisions to Earnings Forecasts for the fiscal year ending March 31, 20235

Presentation Materials for FY2024 2Q financial results

Financial Results and Supplement for FY2024 2Q

Receives U.S. FDA Fast Track Designation for the Novel Anti-Respiratory Syncytial Virus Drug Candidate S-337395

IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously Ill Patients

Regarding the Conclusion of Sales Partnership Agreement with Nxera Pharma Japan for the Insomnia Treatment “QUVIVIQ®”

Regarding the Reorganization and Liquidation of Wholly-Owned Subsidiaries through Absorption-Type Company Split

Shionogi Submits New Drug Application in Japan for Zuranolone as a Treatment for Major Depressive Disorder

Notice Regarding Stock Split, Partial Amendment to Articles of Incorporation and Revision of Dividend Forecast

Shionogi to Announce Personnel Reassignment

New Drug Application of Novel Siderophore Cephalosporin Antibiotics, Cefiderocol, Accepted in China

Transcript of FY2024 1Q Results Meeting

Presentation Materials for FY2024 1Q financial results

Financial Results and supplement for FY2024 1Q

Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Notice of Head Office Relocation

Domestic Launch of the In Vitro Diagnostic Pharmaceutical "Shionogi MIC Dry Plate Cefiderocol"

Shionogi Presented New Clinical Data on the COVID-19 Treatment Ensitrelvir

COVGOZE® for Intramuscular Injection (Monovalent: Original Strain), Recombinant Protein COVID-19 Vaccine, Approved for Manufacturing and Marketing as Initial Immunization in Japan

Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Transcript of R&D Day Follow-up Meeting

Transcript of R&D Day 2024

Presentation Materials for R&D Day

Option Agreement with Cilcare for Development Compounds Addressing Hearing Loss

Shionogi Awarded the Imperial Invention Prize

Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats

Position and Policy Regarding Reduction of the Investment Unit

Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections

Launch of the Gram-negative Bacterial Infection Treatment "FETROJA® (Cefiderocol) 1g" in Taiwan

Transcript of FY2023 Financial Results

Presentation Materials for FY2023 financial results

Financial Results and supplement for FY2023

Shionogi Provides Updates from SCORPIO-HR, a Global Phase 3 Study of Ensitrelvir for Non-Hospitalized Participants with COVID-19

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease

Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Preventive Drugs with Nagasaki University, National Institute of Infectious Diseases, and MMV, Supported by the GHIT Fund

Notice of Revisions to Dividend Forecasts (Dividend Increase)

Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents

ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections

Notice Regarding Completion of Cancellation of Treasury Shares (Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act)

Shionogi Announces Approval of XOFLUZA® (Baloxavir Marboxil) in Taiwan for Pediatrics Aged 5 to <12 years for Treating and Preventing Influenza

The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome

Regarding Support for Earthquake Relief Efforts in Eastern Taiwan

Notice Regarding the Status and Completion of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating (Climate Change) by CDP for the Fourth Consecutive Year

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Shionogi Announces Xocova® (Ensitrelvir Fumaric Acid) Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection

Shionogi Announces the Initiation of the Second Phase of Comprehensive Cooperation in the Field of Infectious Diseases Focused on Malaria with Nagasaki University

Announcement of Option Agreement between FunPep and SHIONOGI Regarding Allergy Vaccine

Shionogi and Osaka University Establish a New Joint Research Lab on Post-COVID-19 Condition (Long COVID)

Shionogi Announces appointment of Auditors, Corporate officers, Corporate Reorganization and Personnel Reassignment

Positive Results from Phase 3 Clinical Trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan

FETROJA® (cefiderocol) Approved by TFDA in Taiwan

Announcement of the Strategic Business Partnership Agreement for Diagnosis Support AI Program in Dementia and Depression between FRONTEO and Shionogi

Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open

Regarding completion of the Transfer of the "Mother to Mother SHIONOGI Project" the Second Phase to the Government of Kilifi County, Republic of Kenya

Recognized with the Double A List for Leadership in Corporate Transparency and Performance on Climate Change and Water Security by CDP for the second consecutive year

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Transcript of the FY2023 3Q Financial Results Conference

Academic Presentation at Neuroscience 2023 in the United States - Confirmation of Gamma Wave Synchronization in the Human Brain through Auditory Stimulation-

Cefiderocol is approved for clinical use in Boao Lecheng International Medical Tourism Pilot Zone, Hainan, China

Financial Results and supplement for FY2023 3Q

Presentation Materials for FY2023 3Q financial results

Notice of Investment Agreement with Niremia Collective

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Announcement of Commencement of DTx Distribution Platform Construction for the Promotion of Digital Therapeutic Services

Regarding the "the ‘2024 (Reiwa 6) Noto Peninsula Earthquake" Disaster Situation